Pipeline

Initial Targeted Indications

Indication
Targeted Subgroup
Formulation
Unique selling point (USP)
© Dale Biotech LLC 2021. All Rights Reserved.
Compensated Cirrhosis NASH
NASH patients who have progressed to compensated cirrhosis
Injectable / Oral
Combination therapy likely to improve efficacy. Improvement in glycemic control; decreases primary drivers of fibrosis.
Cellulite
Cellulite of lateral and posterior buttocks
subcutaneous – injectable
direct action of adipocytes

Additional Development Opportunities

Indication
Targeted Subgroup
Formulation
Unique selling point (USP)
© Dale Biotech LLC 2021. All rights reserved.
Uncontrolled Type 2 diabetes mellitus
(T2DM)
Overweight and requiring insulin
Injectable
Unique short term treatment reduces body weight and improves glycemic control and reduces cardiovascular risk (CV) factors
Body Sculpting
Double chin
Injectable
Significantly less inflammation than currently marketed injectable; Single treatment efficacy expected to be sufficient in majority of clients
Central abdominal bulge
Injectable
No available injectable
Dupuytren’s Disease
Progressive contractures post hand surgery or Xiaflex injection(s)
Injectable sustained release
Large unmet medical need for effective disease modifying treatment
Progressive contractures post hand surgery or Xiaflex injection(s)
Topical
Large market for effective treatment that can be patient-administered